Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cenovus Energy Inc (CVE) vs Cytokinetics Inc (CYTK) Price & Performance

Cenovus Energy IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Cenovus Energy Inc vs Cytokinetics Inc — how do they compare? Cenovus Energy Inc trades at $29.91 (market cap $55.00B), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Cenovus Energy Inc is far larger — about 5.2× Cytokinetics Inc's market cap, and Cenovus Energy Inc pays a 2.09% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CVECYTK
Market Cap
$55.00B$10.63B
Sector
EnergyTechnology
52-Week High
$31.80$87.26
52-Week Low
$14.83$34.31
Enterprise Value
$61.08B$10.74B
Dividend Yield
2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cenovus Energy Inc

Cenovus Energy (CVE) trades at $30.14, up 1.96% with bullish technical signals and strong fundamentals. The stock shows robust earnings momentum with recent quarterly beats, supported by record oil sands production and disciplined cost management. Valuation metrics remain attractive with P/E of 11.56 and EV/EBITDA of 5.77, while profitability metrics include 11.48% net income margin and 20.96% ROE. Recent news highlights institutional buying interest and strong Q2 2026 operational performance.

CVE presents a compelling investment case with undervalued metrics and positive earnings trajectory, though exposure to volatile oil prices and refining margins poses risks. Analyst consensus leans bullish with 40.7% buy ratings, while technical indicators suggest continued upward momentum. The company's integrated model and growth projects support long-term value creation for shareholders.

Cytokinetics Inc

CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.

The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.

Returns comparison

Trailing returns across standard periods

About Cenovus Energy Inc

Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.

Read more on CVE

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK